MAP2K7 and melanoma: Moreover, combination therapy using BRAF inhibitors in conjunction with inhibitors targeting the down‐stream protein MEK has been proven to significantly prolong the overall survival of melanoma patients with BRAF V600 mutations, which represents about 50% of all melanoma cases (Ascierto et al. 2020).